July 23 - 25, 2020

Live Webcast

All times will be in Pacific Time

The 21st Annual International Lung Cancer Congress^® will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will provide perspectives on how to apply the latest data on targeted agents, immunotherapy, surgery, and radiation oncology in the clinic. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with the faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

This activity is supported by educational grants from Amgen, Inc.; AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Jazz Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Takeda Oncology.

Physicians' Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC, designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 20.5 Contact Hours.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.

• Identify biomarkers and testing strategies to optimize selection of therapy in patients with lung cancer
• Evaluate emerging evidence concerning the management of patients with non-metastatic lung cancer
• Apply recent data sets on single-agent and combination immunotherapeutic approaches to care for patients with advanced thoracic malignancies
• Assess recent clinical data on targeted and cytotoxic strategies for the management of patients with thoracic malignancies
• Discuss optimal and personalized sequencing strategies utilizing clinical trial evidence, performance status, and tumor characteristics
• Describe the current status of current clinical trials or approaches to address variances in care for patients with thoracic malignancies

David R. Gandara, MD
Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA